| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 08/25/2004 | EP1448202A1 Combination of a pde4 or pde3/4 inhibitor and an anti-rheumatic drug |
| 08/25/2004 | EP1448194A1 Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| 08/25/2004 | EP1448193A1 Therapeutic compounds for treating dyslipidemic conditions |
| 08/25/2004 | EP1448192A2 Novel methods of treating local fungal and bacterial infections |
| 08/25/2004 | EP1448190A2 Salts formed of an at1-receptor antagonist and a cardiovascular agent |
| 08/25/2004 | EP1448187A2 Compounds derived from an amine nucleus and pharmaceutical compositions comprising same |
| 08/25/2004 | EP1448186A1 Medicament for the treatment of viral skin and tumour diseases |
| 08/25/2004 | EP1448184A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie s disease |
| 08/25/2004 | EP1448182A1 Pharmaceutical compositions and methods for administering ep 2 receptor selective agonists |
| 08/25/2004 | EP1448179A1 Substituted bicyclo 3.3.1 nonan-2,4,9-triones as pharmaceutical active ingredients |
| 08/25/2004 | EP1448176A2 Utilization of inhibitors of rho-kinases for stimulating nerve growth, inhibiting scar tissue formation and/or reducing a secondary lesion |
| 08/25/2004 | EP1448174A2 Water soluble nanoparticles of hydrophilic and hydrophobic active materials |
| 08/25/2004 | EP1448168A1 Pharmaceutical formulation comprising bicalutamide |
| 08/25/2004 | EP1448155A1 Use of at least one abl, kit and/or platelet-derived growth factor receptor tyrosine kinases inhibitor for treating hair depigmentation |
| 08/25/2004 | EP1448152A2 Methods and compositions for the treatment and diagnosis of pain disorders using 2047 |
| 08/25/2004 | EP1448151A1 Dosage form, device and methods of treatment |
| 08/25/2004 | EP1448150A2 Treatment of hyperproliferative diseases using active vitamin d analogues |
| 08/25/2004 | EP1448127A1 Compositions for the treatment of infectious diseases |
| 08/25/2004 | EP1448089A2 Devices and methods for the restoration of a spinal disc |
| 08/25/2004 | EP1448053A2 Proliferation and differentiation of stem cells using extracellular matrix and other molecules |
| 08/25/2004 | EP1448051A2 Methods and formulations for minimizing spasticity in blood vessel grafts |
| 08/25/2004 | EP1372641A4 Enteral formulation |
| 08/25/2004 | EP1360957A4 Vitamin/mineral complex |
| 08/25/2004 | EP1212067A4 Uses of diterpenoid triepoxides as an anti-proliferative agent |
| 08/25/2004 | EP0830130B1 Tnf-alpha converting enzyme |
| 08/25/2004 | CN1524122A Isocitrate dehydrogenase, gene thereof, and use of the same in the treatment of obesity, hyperlipidemia, and fatty liver in lipid biosynthesis |
| 08/25/2004 | CN1524082A Beta-amino tetrahydroimidazo (1,2-a) pyrazines and ahydrotrioazolo (4,3-a) pyrazines as dipeptidyl idase inhibitors for the treatment or prevention of diabetes |
| 08/25/2004 | CN1524003A Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 08/25/2004 | CN1524002A Treatment or prophylaxis of insulin-producing cell graft rejection |
| 08/25/2004 | CN1523993A Antithrombogenic platiniferous ceramic composition and article containing the same |
| 08/25/2004 | CN1523991A Use of c-Src inhibitors alone or in combination with STI571 for the treatment of leukaemia |
| 08/25/2004 | CN1523989A Inhibitors of macrophage migration inhibitory factor and methods for identifying the same |
| 08/25/2004 | CN1523987A Immune response modifiers for the treatment of periodontal disease |
| 08/25/2004 | CN1523986A Substituted oxazolidinones for combinational therapy |
| 08/25/2004 | CN1523985A Preparation of formulations of angiotensin ii at1 receptors antagonists for the treatment of arterial hypertension, other cardiovascular illnesses and its complications |
| 08/25/2004 | CN1523980A Pharmaceutical preparation comprising an active dispersed on a matrix |
| 08/25/2004 | CN1523979A Pharmaceutical compositions of adsorbates of amorphous drug |
| 08/25/2004 | CN1522701A Epoxy-steroidal aldosterone antagonist and angiotensin ii antagonist combination therapy |
| 08/25/2004 | CN1522697A Prevention of migraine recurrence |
| 08/25/2004 | CN1163272C Application of TNF antagonists as medicaments for treating septic diseases |
| 08/25/2004 | CN1163235C Antiviral linear polymer |
| 08/25/2004 | CN1163224C Drugs for improving vesical excretory capacity |
| 08/24/2004 | US6780997 Such as dibenzyl(a,3-o-isopropylidiene-3-hydroxy-4-hydroxymethyl-2-methyl-5-pyridyl) hydroxymethylphosphonate which functions like pyridoxal-5'-phosphate in vivo; drug screening; antidiabetic agents |
| 08/24/2004 | US6780971 Compositions for inhibiting the aggregation pathway of α-synuclein |
| 08/24/2004 | US6780890 Contacting s-adenosylhomocysteine (sah with a luxs protein whereby s- adenosylhomocysteine undergoes conversion to autoinducer-2 |
| 08/24/2004 | US6780882 Substituted benzimidazole dosage forms and method of using same |
| 08/24/2004 | US6780871 Administering to patient a first alpha 3 beta 4 nicotinic receptor antagonist and a second different alpha 3 beta 4 nicotinic receptor antagonist |
| 08/24/2004 | US6780866 Analgesic composition and method |
| 08/24/2004 | US6780849 Nitric-oxide releasing lipid molecules selected from phosphoglycerides, lipids having a sphingosine base as a backbone, a monoglyceride, a diglyceride, a glycosylacylglycerol and a sterol containing s-n=o, n-n=o or |
| 08/24/2004 | US6780839 Use of secretin-receptor ligands in treatment of cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD) |
| 08/24/2004 | US6780838 Compounds for treating fungal pathologies of the oral cavity |
| 08/24/2004 | US6780642 Association of SIM2 with cancer |
| 08/24/2004 | US6780626 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 08/24/2004 | US6780611 G protein coupled receptors; drug screening |
| 08/24/2004 | US6780609 High bone mass gene of 1.1q13.3 |
| 08/24/2004 | US6780427 Superoxide dismutase or other antioxidant are directly applied in combination with polymeric hydrogels at local sites of tissue injury to prevent or decrease formation of adhesions and undesirable proliferation of cells |
| 08/24/2004 | US6780400 Delivery of antiemetics through an inhalation route |
| 08/24/2004 | US6780399 Delivery of stimulants through an inhalation route |
| 08/24/2004 | CA2201784C Method and formulation of stimulating nitric oxide synthesis |
| 08/24/2004 | CA2143610C Use of norastemizole for the treatment of allergic disorders |
| 08/24/2004 | CA2065051C Improved use of .beta.2 bronchodilator drugs |
| 08/19/2004 | WO2004070044A1 Biologically-active-molecule-enriched photosynthetic micro-organisms, preparation method thereof and uses of same |
| 08/19/2004 | WO2004069999A2 Screening method |
| 08/19/2004 | WO2004069855A1 Novel glycosyl transferase with consideration of activity expression mechanism and method of producing the same |
| 08/19/2004 | WO2004069822A1 Composition for inhibiting steroid side effect |
| 08/19/2004 | WO2004069338A1 Use of combinations of h1 and h3 histamine receptor antagonists for the preparation of a medicament for the treatment of allergic skin and allergic ocular conditions |
| 08/19/2004 | WO2004069274A2 Sensitizing cells for apoptosis by selectively blocking cytokines |
| 08/19/2004 | WO2004069267A1 Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases |
| 08/19/2004 | WO2004069259A1 Remedy for diabetes |
| 08/19/2004 | WO2004069254A2 Use of dipyridamole or mopidamole for treatment and prevention of mmp-9-dependent disorders |
| 08/19/2004 | WO2004069252A1 Cabergoline for the prophylactic treatment of migraine |
| 08/19/2004 | WO2004069242A1 Anthelmintic composition |
| 08/19/2004 | WO2004069229A1 Dual release anti-diabetic drugs and process of production thereof |
| 08/19/2004 | WO2004069213A2 Cosmetic composition comprising a 2-alkylideneaminooxyacetamide |
| 08/19/2004 | WO2004069209A2 Compositions and methods for increasing the sensitivity of apoptosis-resistant tumor cells to inducers of apoptosis |
| 08/19/2004 | WO2004069168A2 Novel antiherpes drug combinations |
| 08/19/2004 | WO2004069166A2 Inhibition of hiv-1 replication by disruption of the processing of the viral capsid-spacer peptide 1 protein |
| 08/19/2004 | WO2004069156A2 Inactivated probiotic bacteria and methods of use thereof |
| 08/19/2004 | WO2004069150A2 Oils enriched with diacylglycerols and phytosterol esters for use in the reduction of cholesterol and triglycerides |
| 08/19/2004 | WO2004069146A2 L-dopa amide derivatives and uses thereof |
| 08/19/2004 | WO2004069143A2 Treatment of inflammatory bowel disease |
| 08/19/2004 | WO2004068969A1 Enteral composition for the prevention and/or treatment of sepsis |
| 08/19/2004 | WO2004047830A3 Pharmaceutical composition comprising a beta-3-adrenoceptor agonist and a serotonin and/or norepinephrine reuptake inhibitor and the use of said composition for treating bladder dysfunction |
| 08/19/2004 | WO2004047732A3 Tocopherol and tocotrienol medicaments |
| 08/19/2004 | WO2004024076A9 Novel compositions and methods for the treatment of immune related diseases |
| 08/19/2004 | WO2003094853A3 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 08/19/2004 | WO2003088958A3 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson’s disease |
| 08/19/2004 | WO2003083067A8 Histone deacetylase inhibitors for the treatment of multiple sclerosis, amyotrophic lateral sclerosis and alzheimer's disease |
| 08/19/2004 | WO2003057134A8 Specific binding agents of human angiopoietin-2 |
| 08/19/2004 | WO2003053364A3 Methods and compositions in treating pain and painful disorders using 1465,1587, 2146, 2207, 32838, 336 and 52908 |
| 08/19/2004 | WO2003051886A8 Pyrazolopyridazine derivatives |
| 08/19/2004 | WO2003032912A8 Treatment of cns disorders using cns target modulators |
| 08/19/2004 | US20040162355 Methods of treating and preventing cerebral function disorders using sibutramine metabolites |
| 08/19/2004 | US20040162353 Alpha-difluoromethylornithine(DFMO) suppresses polyamine levels in the human prostate |
| 08/19/2004 | US20040162346 Methods of cardioprotection using dichloroacetate in combination with an inotrope |
| 08/19/2004 | US20040162344 Effective ingredient and basic agent; foam suppression |
| 08/19/2004 | US20040162322 Reducing stimulant dependence; dopamine antagonist; administering pramipexole |
| 08/19/2004 | US20040162319 For prophylaxis and therapy of thrombotic conditions including coronary artery and cerebrovascular diseases |
| 08/19/2004 | US20040162316 Combination treatment for alcoholism and alcohol dependence |
| 08/19/2004 | US20040162314 Enzyme inhibitors of phosphordiesterase 4 having minimal side effects; antiinflammatory agents; antiallergens; asthma; neurodegenerative disorders; antidiabetic agents; pain; anti-tumor, -carcinogenic and -arthritic agents |